Pharmacotherapy of acute respiratory distress syndrome

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 875-888

  dos Santos, C C ^a   Chant, C ^a   Slutsky, A S ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Acute respiratory distress syndrome; Lung; Oxidative stress; Perfusion; Ventilation

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALMITRINE; ARTIFICIAL LUNG SURFACTANT; CORTICOSTEROID DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE INHIBITOR; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HEME OXYGENASE 1; IBUPROFEN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LISOFYLLINE; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; METALLOPROTEINASE INHIBITOR; NEUTROPHIL INHIBITORY FACTOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTAGLANDIN SYNTHASE INHIBITOR; SALMETEROL; THROMBOXANE RECEPTOR BLOCKING AGENT; UNINDEXED DRUG; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; FGF7 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 10; KERATINOCYTE GROWTH FACTOR; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEUKOCYTE FUNCTION; LONG TERM CARE; LUNG VENTILATION PERFUSION RATIO; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RESPIRATORY DISTRESS; REVIEW; ACUTE DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; CELL MOTION; LUNG VENTILATION; METABOLISM; NEUTROPHIL; THROMBOSIS;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANIMAL; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CELL MOVEMENT; FIBROBLAST GROWTH FACTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMAN; INTERLEUKIN-10; NEUTROPHILS; OXIDATIVE STRESS; PULMONARY VENTILATION; RESPIRATORY DISTRESS SYNDROME, ADULT; THROMBOSIS; VASODILATOR AGENTS; ANIMALS; FIBROBLAST GROWTH FACTOR 7; HUMANS;

EID: 0035987558     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.875     Document Type: Review

References (113)

1. Acute respiratory distress in adults
2. Improved survival of patients with acute respiratory distress syndrome (ARDS):1983-1993
3. Improved prognosis of acute respiratory distress syndrome 15 years on
4. The acute respiratory distress syndrome
5. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome
6. Treatment of ARDS
7. The acute respiratory distress syndrome
8. An evidence-based approach to acute respiratory distress syndrome
9. Evidence-based medicine or fuzzy logic: What is best for ARDS management?
10. Thirty years of clinical trials in acute respiratory distress syndrome
11. Acute respiratory distress syndrome: 30 years later
12. Acute respiratory distress syndrome: Pharmacological treatment options in development
13. Pharmacological adjuncts to mechanical ventilation in acute respiratory distress syndrome
14. Treatment of acute (Adult) respiratory distress syndrome. The holy grail of surfactant therapy
15. Ancillary therapies for acute respiratory distress syndrome
16. Surfactant and the acute respiratory distress syndrome (ARDS). Critical care rounds
17. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome
18. Treatment of ARDS with rSP-C surfactant
19. Bovine surfactant therapy for patients with acute respiratory distress syndrome
20. Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS
21. Ventilation strategies affect surfactant aggregate conversion in acute lung injury
22. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized Phase II trial
23. Inhalation of nitric oxide in acute lung injury: Results of a European multicentre study
24. Efficiency of inhaled nitric oxide as rescue therapy during severe ARDS: Survival and factors associated with the first response
25. Effect of inhaled nitric oxide on key mediators of the inflammatory response in patients with acute lung injury
26. The ARDS Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network
27. Short-term effects of inhaled nitric oxide and prone position in pulmonary and extrapulmonary acute respiratory distress syndrome
28. Comparison of the effects of intravenous almitrine and positive end-expiratory pressure on pulmonary gas exchange in adult respiratory distress syndrome
29. Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome
30. Almitrine effect on nitric oxide inhalation in adult respiratory distress syndrome
31. Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome
32. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome
33. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome
34. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome
35. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial
36. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure
37. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response
38. Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension
39. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity
40. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension
41. Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome
42. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection
43. The effects of ibuprofen on the physiology and survival of patients with sepsis
44. Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia
45. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid
46. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome
47. Ketoconazole prevents acute respiratory failure in critically ill surgical patients
48. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome
49. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial
50. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis
51. Leukocyte traffic in the lung
52. Mechanisms of the adult respiratory distress syndrome: Selectins
53. Adhesion molecules and inflammatory injury
54. Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8)
55. CXC chemokine redundancy ensures local neutrophil recruitment during acute inflammation
56. The effect of pentoxifylline on acid-induced alveolar epithelial injury
57. An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome
58. Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons
59. Attenuation of ventilator-induced acute lung injury in an animal model by inhibition of neutrophil adhesion by leumedins (NPC 15669)
60. Beta(2)-Integrin blockade driven by E-selectin promoter prevents neutrophil sequestration and lung injury in mice
61. Antibody to intercellular adhesion molecule 1 (CD54) decreases survival and not lung injury in baboons with sepsis
62. In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2
63. Attenuation of oxidant-induced lung injury by the synthetic matrix metalloproteinase inhibitor BB-3103
64. Metalloproteinase inhibitor prevents acute respiratory distress syndrome
65. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass
66. Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: Attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340)
67. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: A prospective, randomized, placebo-controlled study
68. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: Results from a prospective, randomized, double-blind study
69. A trial of antioxidants N-acetylcysteine and procysteine in ARDS
70. Treatment with N-acetylcysteine during acute respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study
71. Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome
72. Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice
73. Adenovirus-mediated transfer of heme oxygenase-1 cDNA attenuates severe lung injury induced by the influenza virus in mice
74. +-ATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedema
75. Adenoviral-mediated overexpression of the NA,K-ATPase beta1 subunit gene increases lung edema clearance and improves survival during acute hyperoxic lung injury in rats
76. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs
77. Alveolar epithelial fluid clearance persists in the presence of moderate left atrial hypertension in sheep
78. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome
79. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation
80. Dopamine stimulates sodium transport and liquid clearance in rat lung epithelium
81. Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans
82. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor
83. Attenuation of lung inflammation by adrenergic agonists in murine acute lung injury
84. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor
85. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
86. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
87. High-dose corticosteroids in patients with the adult respiratory distress syndrome
88. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock
89. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome
90. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial
91. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats
92. Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy
93. Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced lung injury
94. Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model
95. Keratinocyte growth factor reduces alveolar epithelial susceptibility to in vitro mechanical deformation
96. KGF prevents hydrogen peroxide-induced increases in airway epithelial cell permeability
97. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment
98. Effects of granulocyte colony-stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator-dependent pneumonia
99. Clinical aspects: From systemic inflammation to 'immunoparalysis'
100. Effects of granulocyte colony-stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator-dependent pneumonia
101. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia
102. Filgrastim in patients with pneumonia and severe sepsis or septic shock
103. Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury
104. IT 9302, a synthetic interleukin-10 agonist, diminishes acute lung injury in rabbits with acute necrotizing pancreatitis
105. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia
106. In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat
107. Modulation of cytokines and chemokines, limited pulmonary vascular bed permeability, and prevention of septicemia and death with ceftriaxone and interleukin-10 in pneumococcal pneumonia
108. Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia
109. Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome
110. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
111. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line
112. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons
113. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation